Vital Therapies, Inc. — 2015 Form 10-K
Filing identity: The supplied filing is for Vital Therapies, Inc. (NASDAQ: VTL), not IMMUNIC, INC. It covers the fiscal year ended December 31, 2015; quarterly figures below compare the three months ended December 31, 2015 with the same 2014 quarter.
Business context and reporting period
Vital Therapies was a clinical-stage biotherapeutics company developing ELAD, an investigational extracorporeal human liver-cell therapy for acute liver failure. It had no approved products and had not generated revenue from its planned principal operations. ELAD was its sole product candidate.
Financial performance, cash flow and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $39.8 million | $39.5 million |
| General and administrative expense | $12.3 million | $10.9 million |
| Total operating expenses | $52.1 million | $50.3 million |
| Net loss | $52.0 million | $47.7 million |
| Net loss per share | $2.07 | $3.54 |
| Cash used in operating activities | $50.0 million | $40.8 million |
Fourth-quarter 2015 operating expenses were $9.9 million and net loss was $9.9 million, compared with $14.0 million and $14.0 million, respectively, in fourth-quarter 2014. Quarterly net loss per share was $0.34 versus $0.59.
At year-end, cash and cash equivalents were $83.4 million, working capital was $78.4 million, total assets were $89.1 million, and stockholders’ equity was $82.3 million. The company reported no debt in the balance sheet presented. It reported $2.0 million of operating lease and purchase obligations, largely due within one year. Management estimated available cash would fund operations into the first quarter of 2018, assuming limited BLA work and no significant commercial buildout, but said additional funding would be needed before VTL-308 topline results.
Financing activities provided $32.4 million in 2015, principally net proceeds from an October follow-on offering. The company sold 6.27 million shares at $5.50 per share for gross proceeds of $34.5 million. No operating margin or commercial gross-margin results were reported because there were no product sales.
Material changes versus prior periods
- Full-year net loss increased by $4.4 million, while operating expenses rose 4% year over year. R&D expense was nearly flat; G&A increased 14%.
- Operating cash use increased by $9.1 million year over year. Year-end cash declined from $102.2 million to $83.4 million.
- VTI-208, a Phase 3 trial in alcohol-induced liver decompensation, failed to meet its primary and secondary endpoints. The company discontinued VTI-210 and VTI-212, postponed most BLA-preparation work, and reduced its workforce by approximately 30%.
- In October, the company raised $32.1 million net through a follow-on stock offering. Shares outstanding increased to 30.47 million at year-end from 23.98 million one year earlier.
Outlook, risks, contingencies and unusual items
- VTL-308: The company planned a new Phase 3 sAAH trial informed by subgroup analyses of VTI-208. The event-driven design called for at least 150 subjects and 55 events at approximately 40 U.S. and European sites. First enrollment was expected in the first half of 2016, with topline data anticipated around mid-2018. Management cautioned that trial success, regulatory approval, and whether one successful trial would suffice were uncertain.
- Subgroup evidence: In VTI-208, the overall intention-to-treat population showed no survival difference (p=0.986; hazard ratio 1.000). A prespecified MELD-under-28 subgroup showed a favorable but not conventionally statistically significant trend (p=0.070). A smaller subgroup defined using multiple criteria showed favorable post-hoc results; these analyses do not establish that VTL-308 will succeed.
- Funding and viability: The company expected continuing losses and negative operating cash flow, had no committed external funding, and warned that it might need to delay or reduce development, pursue financing or collaborations, or consider business alternatives if funding or clinical progress proved inadequate.
- Litigation: Two securities class actions alleged misleading statements concerning the company’s clinical trials. The company intended to defend the cases; it said a loss range could not be reasonably estimated and recorded no liability. Legal defense costs were expensed as incurred.
- Other risks: ELAD’s clinical and regulatory prospects, trial enrollment and safety, manufacturing and single-source suppliers, reimbursement and pricing, and the need for additional capital were material uncertainties. The application for marketing approval in China remained under review, but the company did not expect meaningful regulatory activity there before U.S. approval.
- Cost outlook: Management expected R&D expense to decline in 2016, reflecting trial timing, the workforce reduction and reduced BLA activities; G&A was expected to rise, principally due to litigation costs.
- Controls and audit: The independent auditor expressed an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end and said previously reported material weaknesses had been remediated; the auditor did not attest to internal controls.
Most important facts for investors to verify
- Confirm the issuer: this is Vital Therapies’ filing, not an Immunic filing.
- Review VTI-208’s failed overall trial results and distinguish them from the subgroup analyses used to design VTL-308.
- Track VTL-308 initiation, enrollment, event accrual, costs, and whether the data timing remains consistent with management’s outlook.
- Assess cash burn against the stated runway and determine the timing, terms, and dilution implications of additional financing.
- Monitor the securities litigation, supplier and manufacturing risks, and any changes to regulatory expectations or the need for a confirmatory trial.